Expanding HIV Prevention Options for Women. PURPOSE 3 is being done in the United States and will include adult cisgender women who have sex with cisgender men.

PURPOSE 3 is evaluating an investigational drug, lenacapavir, and is enrolling cisgender adult women. This trial is taking place in the United States. Learn ... Purpose 3 · PURPOSE 3 FAQs · Purpose 1 · Purpose 2

24 июл. 2024 г. · We conducted a phase 3, double-blind, randomized, controlled trial involving adolescent girls and young women in South Africa and Uganda.

18 окт. 2023 г. · PURPOSE 3 will study lenacapavir for PrEP among cisgender women in the United States who are disproportionately affected by HIV, with a ...

The goal of this clinical study is to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir ...

10 июн. 2022 г. · Objective:A Randomized, Open-Label Study of Acceptability and Use of Lenacapavir vs TDF/FTC Among US WomenStudy is planned as of Dec 2021 ...

PURPOSE 3 will study lenacapavir for PrEP among cisgender women in the United States who are disproportionately affected by HIV, with a focus on Black women ...

22 июн. 2024 г. · PURPOSE 3 and 4 are smaller US-based studies enrolling, respectively, cisgender women and people who inject drugs – the latter is only the ...

Recruiting Trials. PURPOSE 3. A phase 2 study of a twice yearly, long-acting injection of Lenacapavir for PrEP in cisgender women in the U.S. ...

20 июн. 2024 г. · The PURPOSE program comprises five HIV prevention trials around the world that are focused on innovation in science, trial design, community ...